product name Trifluoperazine 2HCl
Description: Trifluoperazine is a dopamine D2 receptor inhibitor with IC50 of 1.1 NM. Trifluoperazine binds to α1A- and α1B-adrenoceptor with Ki value of 27.6 nM and 19.2 nM, respectively, with α1B/α1A ratio of 0.7. Trifluoperazine inhibits Mycobacterium tuberculosis (Mtb) with MICs of 7.6 μg/mL. Trifluoperazine (< 14.78 mM) suppresses the activities of the mouse splenic NK cell cytotoxicity and the effector-target cell conjugation in a dose dependent manner.
References: Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4; J Pharmacol Exp Ther. 1999 Aug;290(2):901-7.
480.42
Formula
C21H24F3N3S.2HCl
CAS No.
440-17-5
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 88 mg/mL (183.2 mM)
Water: 96 mg/mL (199.8 mM)
Ethanol: 96 mg/mL (199.8 mM)
Solubility (In vivo)
Synonyms
SKF5019
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19397192
| In Vitro |
In vitro activity: Trifluoperazine binds to α1A- and α1B-adrenoceptor with Ki value of 27.6 nM and 19.2 nM, respectively, with α1B/α1A ratio of 0.7. Trifluoperazine inhibits Mycobacterium tuberculosis (Mtb) with MICs of 7.6 μg/mL. Trifluoperazine (< 14.78 mM) suppresses the activities of the mouse splenic NK cell cytotoxicity and the effector-target cell conjugation in a dose dependent manner. Trifluoperazine suppresses interferon-alpha or interleukin-2 induced augmentation of the cytolytic activity of NK cells. Trifluoperazine inhibits the gene expression of voltage-dependent potassium channel Kv2.1 from human brain (hKv2.1). Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Trifluoperazine dose dependently decreases avoidance responses and increases response failures in rats where behavior is maintained under a discrete-trial avoidance. |
| Animal model | |
| Formulation & Dosage | |
| References | Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4; J Pharmacol Exp Ther. 1999 Aug;290(2):901-7. |
Related Posts
product name Trifluoperazine 2HCl
Description: Trifluoperazine is a dopamine D2 receptor inhibitor with IC50 of 1.1 NM. Trifluoperazine binds to α1A- and α1B-adrenoceptor with Ki value of 27.6 nM and 19.2 nM, respectively, with α1B/α1A ratio of 0.7. Trifluoperazine inhibits Mycobacterium tuberculosis (Mtb) with MICs of 7.6 μg/mL. Trifluoperazine (< 14.78 mM) suppresses the activities of the mouse splenic NK cell cytotoxicity and the effector-target cell conjugation in a dose dependent manner.
References: Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4; J Pharmacol Exp Ther. 1999 Aug;290(2):901-7.
480.42
Formula
C21H24F3N3S.2HCl
CAS No.
440-17-5
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 88 mg/mL (183.2 mM)
Water: 96 mg/mL (199.8 mM)
Ethanol: 96 mg/mL (199.8 mM)
Solubility (In vivo)
Synonyms
SKF5019
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19397192
| In Vitro |
In vitro activity: Trifluoperazine binds to α1A- and α1B-adrenoceptor with Ki value of 27.6 nM and 19.2 nM, respectively, with α1B/α1A ratio of 0.7. Trifluoperazine inhibits Mycobacterium tuberculosis (Mtb) with MICs of 7.6 μg/mL. Trifluoperazine (< 14.78 mM) suppresses the activities of the mouse splenic NK cell cytotoxicity and the effector-target cell conjugation in a dose dependent manner. Trifluoperazine suppresses interferon-alpha or interleukin-2 induced augmentation of the cytolytic activity of NK cells. Trifluoperazine inhibits the gene expression of voltage-dependent potassium channel Kv2.1 from human brain (hKv2.1). Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Trifluoperazine dose dependently decreases avoidance responses and increases response failures in rats where behavior is maintained under a discrete-trial avoidance. |
| Animal model | |
| Formulation & Dosage | |
| References | Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4; J Pharmacol Exp Ther. 1999 Aug;290(2):901-7. |